跳至主要内容
临床试验/NCT00170768
NCT00170768已完成2 期

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

Novartis1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2005年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Novartis
入组人数
150
试验地点
1
主要终点
Cognitive effect: measure of accuracy of delayed recall name-phase association test at week 3.

研究概览

简要总结

The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females aged 60 and over
  • United States English as a primary language
  • Given written informed consent by signing and dating an informed consent form prior to study entry

排除标准

  • Current diseases in which the use of anti-cholinergic drugs is contraindicated, including the use of drugs with anti-cholinergic effects
  • Volunteers with history of urinary retention or current bladder outlet obstruction, as determined by the investigator
  • Other protocol defined inclusion/exclusion criteria may apply.
  • Current use of drugs known to effect memory and cognition Other protocol-defined inclusion/exclusion criteria may apply

研究组 & 干预措施

1

Experimental

Darifenacin

干预措施: Darifenacin (Drug)

2

Active Comparator

Oxybutynin

干预措施: Oxybutynin (Drug)

3

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Cognitive effect: measure of accuracy of delayed recall name-phase association test at week 3.

次要结局

  • Cognitive effect: measure of accuracy of delayed recall name-phase association test at week 1 & 2.
  • Effects on other cognitive domains measured by various tests at week 1,2 and 3.

研究者

发起方
Novartis
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Cognitive Effects of Darifenacin and Oxybutynin... | 临床试验